MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

130.20 +0.41 (+0.32%)
Official Closing Price Updated: 7:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Top dow jones movers in Friday's session ↗
Via Chartmill
News headline image
1 Cash-Producing Stock with Promising Prospects and 2 That Underwhelm
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
Wednesday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
News headline image
Merck Announces Fourth-Quarter 2026 Dividend
From Merck & Co., Inc.
Via Business Wire
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
Exploring the top movers within the dow jones index during today's session. ↗
Via Chartmill
Monday's session: top gainers and losers in the dow jones index ↗
Via Chartmill
Explore the top gainers and losers within the dow jones index in today's session. ↗
Via Chartmill
News headline image
Merck Announces Initial Access Plans for Alimatravir, an Investigational Once-Monthly Oral HIV Pre-Exposure Prophylaxis in Phase 3 Development
From Merck & Co., Inc.
Via Business Wire
News headline image
2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗
There are plenty of reasons to love these companies. 
Via The Motley Fool
News headline image
Is Pfizer's 7% Dividend Yield Too Good to Be True? Here's the Straight Answer ↗
Income seekers shouldn't give up on the stock yet. 
Via The Motley Fool
These dow jones stocks are moving in today's session ↗
Via Chartmill
What's going on in today's session: dow jones movers ↗
Via Chartmill
News headline image
1 Dow Jones Stock with Exciting Potential and 2 Facing Headwinds
While the Dow Jones (^DJI) represents industry leaders, not every stock in the index is a safe bet. Some are facing headwinds like declining demand, rising c... 
Via StockStory
Topics Artificial Intelligence Stocks
These dow jones stocks are moving in today's session ↗
Via Chartmill
Stay informed with the top movers within the dow jones index on Tuesday. ↗
Via Chartmill
Which dow jones stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Stay informed with the top movers within the dow jones index on Monday. ↗
Via Chartmill
Uncover the latest developments among dow jones stocks in today's session. ↗
Via Chartmill
These dow jones stocks are moving in today's session ↗
Via Chartmill
Top dow jones movers in Friday's session ↗
Via Chartmill
Which dow jones stocks are moving on Thursday? ↗
Via Chartmill
News headline image
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
From Merck & Co., Inc.
Via Business Wire
What's going on in today's session: dow jones movers ↗
Via Chartmill
Stay informed with the top movers within the dow jones index on Wednesday. ↗
Via Chartmill
Get insights into the top movers in the S&P500 index of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026
From Merck & Co., Inc.
Via Business Wire
News headline image
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story